

# INVITATION TO COMMENT ON EFRAG'S ASSESSMENTS ON IFRS 9 Financial Instruments

Comments should be sent to commentletters@efrag.org by 30 June 2015

EFRAG has been asked by the European Commission to provide it with advice and supporting material on IFRS 9 *Financial Instruments* ('IFRS 9' or 'the Standard'). In order to do that, EFRAG has been carrying out an assessment of IFRS 9 against the technical criteria for endorsement set out in Regulation (EC) No 1606/2002 and has also been assessing impact of IFRS 9 on the European public good.

A summary of IFRS 9 is set out in Appendix 1 to the draft endorsement advice letter.

Before finalising its assessments, EFRAG would welcome your views on the issues set out below and any other matters that you wish to raise. Please note that all responses received will be placed on the public record, unless the respondent requests confidentiality. In the interest of transparency EFRAG will wish to discuss the responses it receives in a public meeting, so we would prefer to be able to publish all the responses received.

EFRAG initial assessments summarised in this questionnaire will be amended to reflect EFRAG's decisions in Appendices 2 and 3 of the draft endorsement advice.

### Your details

Plea	ise provide t	he following details about yourself:				
(a)	Your name:	Your name or, if you are responding on behalf of an organisation or company, its name:				
	Deutsche	Bank Aktiengesellschaft (herein referred to as DB)				
(b)	Are you a:					
	X Prepare	r 🔲 User 🔲 Other (please specify)				
(c)	Please provide a short description of your activity:					
	Deutsche comprising	Bank is a global bank with diversified corporate divisions g of the following businesses:				
	(i)	Corporate Banking and Securities				
	(ii)	Global Transaction banking				
	(iii)	Asset Wealth Management				
	(iv)	Private and Business Clients				
(d)	Country w	here you are located:				
	Headquar	tered in Germany, with operations globally.				

(e) Contact details including e-mail address:

Maria Nordgren, Technical Director, Accounting Policy and Advisory Group, Deutsche Bank AG. Email: <a href="mailto:maria.nordgren@db.com">maria.nordgren@db.com</a> Telephone: +44 (207) 547 5363

Lisa Bomba, Head of the Accounting Policy and Advisory Group, Deutsche Bank AG. Email: <a href="mailto:lisa.bomba@db.com">lisa.bomba@db.com</a> Telephone: +44 (207) 547 1080

# EFRAG's initial assessment with respect to the technical criteria for endorsement

2	endo and com	AG's initial assessment of IFRS 9 is that it meets the technical criteria for orsement. In other words, it is not contrary to the principle of true and fair view it meets meet the criteria of understandability, relevance, reliability and parability and leads to prudent accounting. EFRAG's reasoning is set out in endix 2, paragraphs 2 to 197 of the draft endorsement advice.
	(a)	Do you agree with this assessment?
		X Yes
		If you do not, please explain why you do not agree and what you believe the implications of this should be for EFRAG's endorsement advice.
3	EFR	AG's initial assessment of IFRS 9 is that it leads to prudent accounting. AG's reasoning is set out in Appendix 2 paragraphs 185 to 191 of the draft presement advice.
	(a)	Do you agree with this assessment?
		X Yes
		If you do not, please explain why you do not agree and what you believe the implications of this should be for EFRAG's endorsement advice.
	(b)	Are there any issues relating to prudence that are not mentioned in Appendix 2 that you believe EFRAG should take into account in its technical evaluation of IFRS 9? If there are, what are those issues and why do you believe they are relevant to the evaluation?
		No, we noted no additional issues that should be mentioned. See also our response to item 5b below.
	(c)	Are there any other issues that are not mentioned in Appendix 2 of the draft

endorsement advice that you believe EFRAG should take into account in its

technical	evaluation	of IFRS 9?	If there	are,	what	are	those	issues	and	why
do you be	elieve they a	are relevant	to the e	valua	ation?					

No, we noted no response to item 5	issues	that	should	be	mentioned.	See	also	our

# The European public good

In its assessment of the impact of IFRS 9 on the European public good, EFRAG has considered a number of issues that are addressed in Appendix 3 of the draft endorsement advice.

IFRS 9 compared to IAS 39

- 5 EFRAG's initial assessment of IFRS 9, and particularly with respect to the impairment and hedging requirements, is that it is an improvement over IAS 39 and will lead to higher quality financial reporting. The assessment is reflected in paragraphs 3 to 52 of Appendix 3 of the draft endorsement advice.
  - (a) Do you agree with this assessment?

Do you agree with this assessment:
X Yes
If you do not, please explain why you do not agree and what you believe the implications of this should be for EFRAG's endorsement advice.

(b) Are there any issues relating to IFRS 9 compared to IAS 39 that are not mentioned in Appendix 3 of the draft endorsement advice that you believe EFRAG should take into account in its technical evaluation of IFRS 9 when comparing to IAS 39? If there are, what are those issues and why do you believe they are relevant to the evaluation?

Deutsche Bank supports a swift endorsement of IFRS 9 for use in the European Union, for the following reasons:

- IFRS 9 is, on the whole, an improvement to the current IAS 39 standard.
- IFRS 9 reduces a significant amount of complexity in the current standard for financial instrument accounting, by requiring a single impairment model and removing the embedded derivatives rules for financial assets. The use of the business model as a key determinant of classification while still considering the characteristics of the instrument provides a clearer principle for determining when amortised cost/fair value through OCI accounting is appropriate. We also support the IASB's decision to address the important issue of "own credit" and its impact on financial liabilities.
- The impairment rules under IFRS 9 address the issue of 'too little too late', by requiring lifetime expected credit losses on those positions for which there has been a significant increase in credit risk since

inception.

- As part of the IASB's due process for all three phases, it has conducted an extensive outreach program on IFRS 9, in which we have actively participated, to ensure that all constituents' concerns and issues were heard and were given due consideration.
- As a result of the due process conducted by the IASB, we believe that the IASB has adequately addressed the concerns we expressed during our discussions with them and in our previous comment letters.

We believe that the principles underpinning the classification of assets, supplemented with the improvements in impairment and hedge accounting and the impacts on own credit for financial liabilities under a FVO, will provide more relevant information to financial statement users which reflects the specific business models of the institution.

Moreover as a foreign private issuer registered with the US Securities Exchange Commission, DB must file IFRS financial statements under full IFRS as approved by the IASB. At the same time, to meet EU regulations, our financial statements must be prepared under IFRS as endorsed by the European Union (EU). Therefore, non endorsement of IFRS 9 by the EU (either in full or in part, say, via carve outs) would impose extremely costly and complex burdens on our organisation, and be potentially confusing to investors, as we must produce two sets of financial statements.

The lack of convergence with US GAAP

6	repor impai	AG's initial assessment is that IFRS 9 will lead to higher quality financial ting when compared to current US GAAP and proposed changes to rment requirements. The assessment is reflected in paragraphs 53 to 74 of ndix 3 of the draft endorsement advice.
	(a)	Do you agree with this assessment?
		X Yes
		If you do not, please explain why you do not agree and what you believe the implications of this should be for EFRAG's endorsement advice.
	(b)	Are there any issues related to the impact of the lack of convergence that are not mentioned in Appendix 3 of the draft endorsement advice that you believe EFRAG should take into account in its technical evaluation of IFRS 9 when comparing with US GAAP? If there are, what are those issues and why do you believe they are relevant to the evaluation?
		No, we do not have additional issues to raise over and above those already stated in paragraphs 53 to 74 in Appendix 3.

EFRAG's analysis in this area is based on our understanding of both changes in IFRS 9 and current practices of financial institutions and is not a full impact

## Impact on investor and issuer behaviour

7

only, being	ssment. In its analysis EFRAG has tried to identify potential negative effects to contribute to identifying whether there would be any impediment to IFRS 9 g conducive to the European public good. The assessment is reflected in graphs 75 to 99 of Appendix 3 of the draft endorsement advice.
(a)	Do you agree with this assessment?
	X Yes
	If you do not, please explain why you do not agree and what you believe the implications of this should be for EFRAG's endorsement advice.
	We agree with the assessment in Appendix 3 that IFRS is, on balance, conducive to the public good because it is an overall improvement to financial reporting as compared to IAS 39
(b)	Are there any issues related to the impact of IFRS 9 on investor and issuer behaviour that are not mentioned in Appendix 3 of the draft endorsement advice that you believe EFRAG should take into account in its technical evaluation of IFRS 9? If there are, what are those issues and why do you believe they are relevant to the evaluation?
	No, we do not have additional issues to raise.

# Inter-relationship of IFRS 9 with the future insurance contracts standard

- 8 EFRAG has initially concluded that the mismatch in timing of the future insurance contracts standard and IFRS 9 will create disruptions in the financial reporting of insurance activities which may not be beneficial to investors and other primary users (see Appendix 3, paragraphs 100 to 110 of the draft endorsement advice). Hence EFRAG proposes to advise the European Commission to ask the IASB to defer the effective date of IFRS 9 for insurers and align it with the effective date of the future insurance contracts standard.
- In reaching this preliminary position, EFRAG has relied on quantitative assessments prepared by the European insurance industry and released shortly before EFRAG concluded on its tentative advice to the European Commission. EFRAG intends to deepen its understanding of the effect on the reporting by insurance businesses by implementing IFRS 9 in advance of the forthcoming IFRS 4. EFRAG invites all quantitative evidence that can supplement the impact assessment received from the European insurance industry, including evidence gathered by those who oppose the deferral.

	Do you agree with this assessment and the subsequent advice to the European Commission?	е
	Yes X No	
	f you do not, please explain why you do not agree and what you believe the mplications of this should be for EFRAG's endorsement advice.	e
	No, DB does not support a deferral of the effective date of IFRS 9 for insurers' for the following reasons:	٢
	• We understand that the IASB is currently investigating approaches which would mitigate the impact from the gap in the effective dates for IFRS 9 and IFRS 4, of which include aligning the measurement of insurance liabilities with that of the assets in between the effective dates of the two standards and affording entities with the ability to refresh the IFRS 9 fair value options when IFRS 4 becomes effective. Therefore any mismatches caused by the different effective dates may not be as significant as originally expected.	f f
	<ul> <li>Failing the above point, in the period between the effective dates of IFRS 9 and the future insurance standard, we believe that any mismatches in financial reporting can be adequately addressed via additional disclosure for that gap period.</li> </ul>	1
	• Were the IASB decide not to grant such deferral for insurers but Europe creates a carve out, such that only European insurers can defer IFRS 9, this would be highly detrimental for IFRS as a global accounting standard. We do not support any carve outs as they destroy the benefits of having global accounting standards and dilutes investor confidence in financial reporting in Europe.	)   /
	<ul> <li>Finally, it is also unclear what the exact scope for such a deferral would be (how would 'insurers' be defined for this purpose) and therefore it is unclear how this could be operationalised.</li> </ul>	
	Do you think that EFRAG should recommend the EC to grant to insurance ousinesses a deferred mandatory date of application for the endorsed IFRS of the IASB were not to defer the effective date of IFRS 9?	
	☐ Yes X No	
	f you do not, please explain why you do not agree and what you believe the mplications of this should be for EFRAG's endorsement advice.	е -
1	See our comments above in 9a	

	(C)	insurance contracts standard that are not mentioned in Appendix 3 of the draft endorsement advice that you believe EFRAG should take into account in its technical evaluation of IFRS 9 when assessing the inter-relationship between IFRS 9 and the future insurance contracts standard? If there are, what are those issues and why do you believe they are relevant to the evaluation?
		See our comments above in 9a
Eur	opean	carve-out
10	the a	AG has initially concluded that the endorsement of IFRS 9 would not affect ability of entities to rely on the European carve-out (see Appendix 3, paragraphs to 117 of the draft endorsement advice).
	(a)	Do you agree with this assessment?
		X Yes
		If you do not, please explain why you do not agree and what you believe the implications of this should be for EFRAG's endorsement advice.
		Please note that DB does not utilise the European carve out and as such does not have a strong view on whether the carve out should be used
	(b)	Are there any issues related to the European carve-out that are not mentioned in Appendix 3 of the draft endorsement advice that you believe EFRAG should take into account in its technical evaluation of IFRS 9 when assessing the EU carve out? If there are, what are those issues and why do you believe they are relevant to the evaluation?
		See our response to 10a above.
_		

# Costs and benefits of IFRS 9

- 11 EFRAG is assessing the costs that are likely to arise for preparers and for users on implementation of IFRS 9 in the EU, both in year one and in subsequent years. Some initial work has been carried out, and the responses to this Invitation to Comment will be used to complete the assessment.
- The results of the initial assessment of costs are set out in paragraphs 120 to 155 of Appendix 3 of the draft endorsement advice. To summarise, EFRAG's initial assessment is that overall, IFRS 9 is likely to result in significant costs for preparers related to implementation of and ongoing costs of complying with the standard. However, IFRS 9 is not likely to result in significant costs for users after the transition. At transition costs will be incurred in understanding the new financial reporting.

	(a)	Do you agree with this assessment?
		X Yes
		If you do not, please explain why you do not and (if possible) explain broadly what you believe the costs involved will be.
	(b)	In addition, EFRAG is assessing the benefits that are likely to be derived from the application of IFRS 9. The results of the initial assessment of benefits are set out in paragraphs 156 to 170 of Appendix 3. To summarise, EFRAG's initial assessment is that overall, users and preparers are both likely to benefit from IFRS 9, as the information resulting from it will be relevant and transparent and therefore will enhance the analysis of users.
		Do you agree with this assessment?
		X Yes
		If you do not agree with this assessment, please provide your arguments and indicate how this should affect EFRAG's endorsement advice.
13		AG's initial assessment is that the benefits to be derived from implementing 5 9 in the EU as described in paragraph 12 (b) above are likely to outweigh the
		s involved as described in paragraph 12 (a) above are likely to outweigh the
	Do y	ou agree with this assessment?
	ΧΥε	es 🗌 No
		ou do not agree with this assessment, please provide your arguments and cate how this should affect EFRAG's endorsement advice.
Ove	rall as	sessment with respect to the European public good
14	to th	AG has initially concluded that endorsement of IFRS 9 would be conducive e European public good (see Appendix 3, paragraphs 174 to 176 of the draft presement advice).
	Do y	ou agree with the assessment of these factors?
	ΧΥε	es 🗌 No
	If yo	u do not agree, please explain your reasons.

We agree with the assessment in Appendix 3 that IFRS is, on balance,	conducive
to the public good because it is an overall improvement to financial re	porting as
discussed in our response to comment 5b.	

#### Other issues for consideration

Request to provide quantitative data on a confidential basis

15	EFRAG continues its search for quantitative data in the fields of impairment and the inter-relationship between IFRS 9 and the future insurance contracts standard. EFRAG calls upon constituents who have quantitative data available in these fields, to provide it to EFRAG on a confidential basis during the consultation period of the draft endorsement advice. Data provided will be used in finalising the endorsement advice but will not be made public.						
	The collection of these data is subject to EFRAG's <u>field-work policy</u> which is available on the EFRAG website.						

Should endorsement be halted until quantitative data are available?

Based on the results of our questionnaire follow up to the field-tests, it can take up to 2017 to have quantitative impacts of the implementation of IFRS 9 available. It has been argued by some that the quantitative impacts of IFRS 9 should be known before endorsement of the standard is decided upon. EFRAG does not agree with this view and believes that the improvements brought to financial reporting by IFRS 9 should not be withheld from European companies for a period that long.

Do you agree with this assessment?

X Yes ☐ No

If you do not, please explain why you do not agree and what you believe the implications of this should be for EFRAG's endorsement advice.

We agree that the endorsement of IFRS 9 should not be delayed until a date that precise quantitative impacts are known. In the most topical area, impairment, the results from the Field Test in Appendix C indicate that higher provisions are expected as a result of IFRS 9 (insofar that none of the participants indicated a decrease in provisions). This is consistent with the objective of IFRS 9 impairment rules — to recognise credit losses earlier. In addition, we believe that the new disclosures regarding credit risk, whose objectives is to enable users to understand an entity's credit risk management practices and exposures, are in improvement to financial reporting and will increase transparency to users.

A delayed endorsement process until 2017 creates uncertainty in implementation projects and may compromise high quality implementation of the accounting and disclosure requirements. Therefore a lack of precise quantitative impact estimates should not preclude the endorsement of IFRS 9.

# IFRS 9 – Invitation to Comment on EFRAG's Assessments

Should early application of IFRS 9 be prohibited?

17	for specific regulated opinion that entities	d industries. should be	at early application of IFRS 9 should not be allowed s. EFRAG does not agree with this and is of the e able to apply IFRS 9 early (see Appendix aft endorsement advice).	ne
	Do you agree with this assessment?			
	X Yes	☐ No		
	If you do not, please explain why you do not agree and what you believe the implications of this should be for EFRAG's endorsement advice.			